CD274 and cancer: PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can cause diverse cutaneous immune-related adverse events (IrAEs) (12–17).There have been instances of severe skin adverse reactions reported after 10 cycles of tislelizumab (18).Therefore, we believe that tislelizumab may lead to skin toxicity.